Back to all DocMorris AG press releases
DocMorris AG
- SIX:DOCM
DocMorris reports 15.2 per cent external revenue growth in Q2 2026
Published
At a glance
- Company
- DocMorris AG
- Listings
- SIX:DOCM
- Announcement type
- Trading update
- Published
- Source announcement
- eqs-news.com
| Measure | Figure | Period | Compared with |
|---|---|---|---|
| External revenue | CHF 309.7 million | second quarter of 2026 | 15.2 per cent vs the same period of the previous year |
| Revenue | CHF 295.4 million | second quarter of 2026 | 16.1 per cent vs the same period of the previous year |
| Active customers | 12.9 million | the second quarter of 2026 | 1.1 million vs year-on-year |
| External revenue | CHF 627.8 million | the first half of 2026 | 12.5 per cent vs the same period last year |
Figures are quoted from this announcement and selected automatically.
FAQSIR Generated from this announcement View original release below for safe harbor and regulatory notices
Announcement Summary
DocMorris AG (DOCM) reported second-quarter 2026 results, including revenue growth in prescription medicines and Digital Services.
- External revenue was CHF 309.7 million in Q2 2026, with 15.2 per cent growth in local currency; revenue was CHF 295.4 million, with 16.1 per cent growth.
- Rx external revenue growth was 45.8 per cent in Q2 2026; Q2 external revenue was 17.2 per cent higher than Q1 2026.
- Non-Rx external revenue increased by 6.7 per cent; OTC business growth was 6.4 per cent. Segment Germany external revenue increased by 15.1 per cent.
- Digital Services revenue grew 80.0 per cent to CHF 13.9 million; it comprises TeleClinic, retail media and marketplace.
- The company expects adjusted EBITDA to improve further in Q2 2026 compared with Q1 2026, which was minus CHF 6.3 million.
- In H1 2026, external revenue was CHF 627.8 million, with 12.5 per cent growth; Rx growth was 38.3 per cent.
The company said the positive impact of H1 2026 performance and the AI-First strategy announced June 25, 2026, on 2026 guidance will be communicated with half-year results on August 19, 2026.
Investor FAQs
DocMorris reported external revenue growth of 15.2% in the second quarter of 2026 to CHF 309.7 million, compared with the same period of the previous year. It also reported accelerated Rx growth of 45.8% and Digital Services growth of 80.0%.
The update covers the second quarter and first half of 2026, compared with the corresponding periods of the previous year. DocMorris said external revenue increased by 12.5% in the first half to CHF 627.8 million.
DocMorris's external revenue increased by 15.2% in the second quarter of 2026 to CHF 309.7 million, while revenue increased by 16.1% to CHF 295.4 million. The percentages are stated by the company in local currency.
DocMorris's external revenue from prescription medicines, or Rx, increased by 45.8% in the second quarter of 2026. Rx external revenue was also 17.2% higher than in the first quarter of 2026.
DocMorris's non-Rx external revenue increased by 6.7% in the second quarter of 2026. Within that figure, the OTC business grew by 6.4%.
DocMorris's Digital Services revenue increased by 80.0% to CHF 13.9 million in the second quarter of 2026, with a further increase in earnings contribution. Digital Services comprises TeleClinic, retail media and marketplace.
DocMorris's active customer base increased year-on-year by 1.1 million to 12.9 million. The total comprised 11.4 million online pharmacy customers and 1.5 million TeleClinic customers, with 0.3 million added in the second quarter of 2026.
CEO Walter Hess attributed the Rx growth and increase in new Rx customers to sustainable growth in the prescription business, while describing Digital Services growth as profitable. CFO Daniel Wüest said the company's focus on operational and marketing efficiency was paying off and that it maintained high marketing efficiency.
DocMorris reported first-half external revenue growth of 12.5% to CHF 627.8 million and revenue growth of 13.4% to CHF 599.2 million. Rx growth was 38.3%, non-Rx increased by 6.6%, and Digital Services grew by 71.4% to CHF 27.1 million.
CFO Daniel Wüest said DocMorris was fully on track to reach EBITDA breakeven during 2026. DocMorris also said adjusted EBITDA was expected to improve further in the second quarter compared with the first quarter of 2026, when it was minus CHF 6.3 million.
CEO Walter Hess said the momentum from the first half of the year gives DocMorris strong tailwinds for the rest of 2026. The company said the impact of its first-half performance and the “AI-First” strategy announced on 25 June on its 2026 guidance will be communicated with the half-year results.
DocMorris AG operates in online pharmacy, telemedicine and marketplace services, with strong brands in Germany and other European countries. Its deliveries are mainly made from its highly automated logistics centre in Heerlen, the Netherlands, while TeleClinic connects patients with more than 6,500 doctors and the company operates health and personal care marketplaces in Southern Europe.
The shares of DocMorris AG are listed on the SIX Swiss Exchange. The source gives securities number 4261528, ISIN CH0042615283 and ticker DOCM.
DocMorris has scheduled its 2026 half-year results for 19 August 2026, with a conference call and webcast. The company said it will communicate the impact of first-half performance and its “AI-First” strategy on 2026 guidance as part of those results.
DocMorris has scheduled a Q3/2026 trading update for 15 October 2026 and a Capital Markets Day in Heerlen, Netherlands, for 12 November 2026. The company has also listed 19 January 2027 for Sales 2026, 18 March 2027 for its 2026 full-year results and outlook for 2027, and 12 May 2027 for its Annual General Meeting in Zurich.
Source announcement
- Company
- DocMorris AG
- Title
- DocMorris reports strong revenue growth of 15% in the second quarter; Rx grows by 46% and Digital Services by 80%
- Published
- Source site
- eqs-news.com
Read the source announcement on eqs-news.com
FAQSIR's summary and investor FAQs are generated by AI from the text of this announcement alone, without information from other sources.
Figures, forecasts and other claims are the announcement's, not FAQSIR's. FAQSIR does not independently verify them.
Read the original press release
Full text as published, unedited.
Loading the original release…